Research Article

Inhibition of Melanoma Angiogenesis by Telomere Homolog Oligonucleotides

Figure 6

T-oligo decrease tumor angiogenesis and melanoma tumor volumes in mouse SCID xenografts. (a) Representative images of 6 μm tumor cross-sections immunostained with CD31 (green) and TopRo-3 (blue-nuclei) and perfused in vivo with BS-1 lectin (red), to determine tumor microvascular density (MVD) per high power field (HPF) ×40 magnification. Both functional and total vessels were examined in 5 mice/group. Arrows indicate CD31 (+) vessels that are considered nonfunctional (not perfused) whereas arrowheads indicate double (+) BS-1 lectin/CD31 vessels that are considered functional (perfused in vivo). (b) Percent functional vessels (red-BS-1 lectin staining) in T-oligo injected mice, taking MVD in vehicle injected mice as 100%. (c) Percent total vessels (green-CD31 staining) in T-oligo injected mice, taking MVD in vehicle injected mice as 100%. (d) SCID mice were injected with MMAN cells into the flank. T-oligo or vehicle was injected daily for up to 5 days when tumors were first palpable (2-3 mm diameter). Average tumor volume/animal was recorded over 4-weeks in 5-6 mice/group.
928628.fig.006a
(a)
928628.fig.006b
(b)
928628.fig.006c
(c)
928628.fig.006d
(d)